19 June 2013
Keywords: ph, ii, nsclc, asa404, trial, supports, earlier
Article | 17 September 2007
UK-based drug developer Antisoma says that data from a study of its anticancer agent ASA404, presented at the World Conference ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 September 2007
18 June 2013
© 2013 thepharmaletter.com